Target Therapeutic Ranges of Anti-MRSA Drugs, Linezolid, Tedizolid and Daptomycin, and the Necessity of TDM.

Abstract

The target therapeutic ranges of vancomycin, teicoplanin, and arbekacin have been determined, and therapeutic drug monitoring (TDM) is performed in clinical practice. However, TDM is not obligatory for daptomycin, linezolid, or tedizolid. In this study, we examined whether TDM will be necessary for these 3 drugs in the future. There was no significant difference in therapeutic effects on acute bacterial skin and skin structure infection between linezolid and tedizolid by meta-analysis. Concerning the therapeutic effects on pneumonia, the rate of effectiveness after treatment with tedizolid was significantly lower than with linezolid. With respect to safety, the incidences of gastrointestinal adverse events and blood/lymphatic system disorders related to tedizolid were significantly lower than those related to linezolid. Linezolid exhibits potent therapeutic effects on pneumonia, but the appearance of adverse reactions is indicated as a problem. There was a dose-dependent decrease in the platelet count, and the target trough concentration (Ctrough) was estimated to be 4-6 or 2-7 µg/mL in accordance with the patient's condition. The efficacy of linezolid may be obtained while minimizing the appearance of adverse reactions by performing TDM. The target therapeutic range of tedizolid cannot be achieved in immunocompromised or severe patients. Therefore, we concluded that TDM was unnecessary, considering step-down therapy with oral drugs, use in non-severe patients, and high-level safety. Concerning daptomycin, high-dose administration is necessary to achieve an area under the curve (AUC) of ≥666 as an index of efficacy. To secure its safety, Ctrough (<20 µg/mL) monitoring is important. Therefore, TDM is necessary.

• Authors: Kazuaki Matsumoto, Masaru Samura, Sho Tashiro, Shino Shishido, Reika Saiki, Wataru Takemura, Kana Misawa, Xiaoxi Liu, Yuki Enoki, Kazuaki Taguchi
• Journal: Biological & pharmaceutical bulletin (Biol Pharm Bull) Vol. 45 Issue 7 Pg. 824-833 ( 2022) ISSN: 1347-5215 [Electronic] Japan
• PMID: 35786589 (Publication Type: Journal Article, Meta-Analysis)

Chemical References

• Oxazolidinones
• Pharmaceutical Preparations
• Tetrazoles
• tedizolid
• Linezolid
• Daptomycin

Topics

• Daptomycin (adverse effects)
• Drug Monitoring
• Humans
• Linezolid (adverse effects)
• Oxazolidinones
• Pharmaceutical Preparations
• Tetrazoles